Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.54 USD
-0.17 (-1.45%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $11.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IOVA 11.54 -0.17(-1.45%)
Will IOVA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
Other News for IOVA
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
First Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)